Viatris

When researching Viatris, analysts typically begin with its Health Care sector positioning and Pharmaceuticals industry dynamics. Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

The company reports trailing twelve-month revenue of $3.52B and net loss of $169.00M. Key metrics include a return on equity of 84.1%, a debt-to-equity ratio of -110.33.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for VTRS to support both active traders and long-term investors.